VC  Healthcare Royalty Partners

     Office Locations:

300 Atlantic Street
Suite 600
Stamford, CT 06901
Phone: 203-388-9080
Fax: 646-562-1293



  • Early



  • Life Sciences & Healthcare



    Healthcare Royalty Partners (CHRP) is a leading global healthcare private equity firm with over $2 billion in capital under management. The firm invests principally in commercial stage healthcare companies and products through the purchase of traditional passive royalties, the creation of Synthetic Royalties: and structured debt and equity instruments. Healthcare Royalty Partners seeks to structure investments that create long-term value for the firm's investors and its three distinct groups of counterparties: (i) healthcare product companies; (ii) academic, research and non-profit institutions; and (iii) inventors. The firm was founded in January 2007 and closed its inaugural fund, Healthcare Royalty Partners, L.P., in July 2008 with over $500 million in capital commitments. CHRP invests in healthcare companies and products across a broad range of therapeutic areas predominately in the U.S. and European Union. The firm targets investments between $20 million and $150 million, but will invest in excess of $100 million under certain circumstances. In December 2011, the firm closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Clarke B. Futch Founding Managing Director
    Gregory B. Brown MD Founding Managing Director
    Matthew Q. Reber Managing Director
    Paul J. Hadden Principal
    Todd C. Davis Founding Managing Director


    Portfolio companies include:

      AEterna Zentaris
        web link

      Astellas Pharma
        web link

        web link

      Fosamprenavir Royalty
        web link

        web link

        web link

      Ledgemont Royalty
        web link

      LifeCycle Pharma
        web link

        web link

      Nuron Biotech
        web link

        web link

      Raptor Pharmaceuticals
        web link

      Suveva Medical
        web link

      TCD Royalty
        web link

        web link

        web link


    Recent News: